Delivery Order SPE2DB20D1109-SPE2DB25FP80Z
- Not listed
- The Defense Logistics Agency awarded a $3,276.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The pharmaceutical will be sourced from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) with a ceiling value of $25,134.02. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed and delivered from...
- The Defense Logistics Agency awarded a delivery order valued at $3,730.96 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg on August 14, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers. This delivery order...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a $21,978.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $23,438.54. This is a firm fixed price delivery order with no set-aside designation, completed through open competition. The order is scheduled for ultimate completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a $28,753.09 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 13, 2025, for the supply of Ondansetron ODT 4mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of October 9, 2025. The contract is fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as one of the nation's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP80ZDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,689.82 for the supply of 500 tablets of Ondansetron HCL 4 mg on September 23, 2025, with an ultimate completion date of September 24, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a discrete purchase under AmerisourceBergen's larger pharmaceutical supply framework. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate office. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support for military healthcare systems globally. Ondansetron, a widely used anti-nausea medication, supports military medical operations and veteran healthcare needs. AmerisourceBergen's extensive federal contract portfolio demonstrates its critical role as a primary pharmaceutical distributor for the Department of Defense, with demonstrated capability to fulfill diverse medical procurement requirements across multiple therapeutic domains at varying order values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/23/25 |